SMi presents the 2nd Annual Conference: Injectable Drug Delivery 2019

SMi Group15 - 16 May 2019, London, UK.
The global injectable drug delivery market is expected to grow from $400 billion to $1200 billion by 2046 with a CAGR of 12.8%. Injectable drug delivery is a method of drug administration into the body with a needle via various routes including intramuscular and intravenous. These are examples of conventional drug delivery. Recently, there has been a focus on novel drug delivery, including needle-free injectors, and transdermal patches. Long acting injectables (LAI) are developing fast as a push towards patient centric devices drives the industry. Habitually, injectables were used for delivery of hormones, vaccines and insulin but as technology advances the application is continuing to expand. Now there is an emphasis on finding solutions to chronic conditions and the biological drugs required involve formulation development challenges for proteins, including high viscosity and high volume. Self-administrative, connected, and ergonomic devices are the new drive. Self-injectable devices include pen injectors for diabetic patients. The wealth of expansion available in the field of connected devices is huge. The regulatory landscape is challenging as it evolves rapidly with the market demand for new devices.

The benefits of attending

Developing on last year's success, this event assembles an international audience to include regulatory, device design, packaging and formulation professionals. The devices need to be designed for the new generation of drugs and they need to provide safety with a strong patient focus. This event is will help inspire you to help drive this industry forward and learn about the predicted market trends, critical digital and chemical developments and the push for patient compliance in a changing regulatory landscape.

This conference offers a chance to learn about innovative injectable drug delivery systems with industrial insights on the following:

  • Life cycle management for developing devices that are both user friendly and revenue effective
  • Device design considerations
  • Long acting injectables and bringing these therapeutics to market with case studies
  • Connected devices, GDPR and cyber security programs
  • Developments in primary packaging
  • Growth in transdermal delivery and subcutaneous infusion devices
  • Digital health partnerships
  • Large volume patch pump innovation examples

Who should attend

Executives, Directors, VPs, Heads, Principals, Managers, Scientists, Researchers of:
  • Autoinjectors
  • Wearables
  • Device Engineering
  • Human Factors
  • CMC
  • Injectables
  • Sterile Manufacturing
  • Packaging
  • Regulatory Affairs

Featured Speakers

  • Bjorg K. Hunter, Device Engineering Manager, GSK
  • Miranda Newbery, Human Factors Consultant, Inspired Usability
  • Blake Green, Regulatory Affairs Senior Manager, Devices, Amgen
  • Quentin Le Masne, Head of Engineering team - Electro-Medical / Drug Delivery Devices, Merck
  • Vasco Filipe, Formulation and Drug Process Development Section Head for Biologics, Sanofi
  • Stephen Paboojian, Senior Project Leader I for Device Development, Novartis
  • Tom Lawrie-Fussey, Digital Services Specialist, Cambridge Design Partnership
  • Terry Reed, Director of Business development, AstraZeneca
  • Joel Richard, Head of Technical and Pharmaceutical Operations, MedinCell

For further information and to register, please visit:
http://www.injectable-drug-delivery.com/worldpharmwl

Early Bird Discounts

  • Book by 31st January and save £400
  • Book by 28th February and save £200
  • Book by 29th March and save £100

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

Aspirin green light for brain bleed stroke patient…

People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major ...

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

APRINOIA Therapeutics awarded grant from The Micha…

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that...

Benralizumab not effective reducing exacerbations …

More than 15.3 million people in the U.S. suffer from chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in this country, according t...

Pfizer announces top-line results from Phase 3 Tri…

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age wi...

Novartis phase II data for new inhaled combination…

Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol ac...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

New data show Symbicort reduces attacks in mild as…

New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol)...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Novartis Kisqali significantly extends life in wom…

Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated K...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...